Work

A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent

Year: 2015

Type: article

Abstract: Meeting abstracts Clinical trials in patients with advanced bladder cancer have reported response rates of up to approximately 30% and 60% with single-agent and multi-agent regimens, respectively, and minimal improvements in survival over best supportive care. Guidance on second-line treatment

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p174

Authors: Padmanee Sharma, Marc-Oliver Grimm, Matthew D Galsky, Ari Baron, Sergio Bracarda, Arlene Siefker-Radtke, Alexandre Lambert, Alex Azrilevich, Margitta Retz

Institutions: The University of Texas MD Anderson Cancer Center, Jena University Hospital, Icahn School of Medicine at Mount Sinai, California Pacific Medical Center, Tumour Institute of Tuscany, Bristol-Myers Squibb (United States), TUM Klinikum, Technical University of Munich

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2189590588

FWCI:

Cites:

Cited by: 1

Related to: 10